Erratum: FasL Gene -844T/C mutation of esophageal cancer in South China and Its clinical significance (Scientific Reports 4 (3866) DOI: 10.1038/srep03866);FasL gene -844T/C mutation of esophageal cancer in South China and its clinical significance

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Zhao, Hongguang ^a   Zheng, Linfeng ^a   Li, Xinru ^b   Wang, Lifang ^c  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; FASLG PROTEIN, HUMAN;

ALLELE; CASE CONTROL STUDY; CHINA; ESOPHAGUS TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; MUTATION; RISK; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

ALLELES; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CHINA; ESOPHAGEAL NEOPLASMS; FAS LIGAND PROTEIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; RISK FACTORS;

EID: 84926429211     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05386     Document Type: Erratum

References (34)

1. Fan, X. Q. & Guo, Y. J. Apoptosis in oncology. Cell Res. 11, 1-7 (2001).
2. Evan, G. I. & Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature. 411, 342-348 (2001).
3. Nagata, S.&Golstein, P. The Fas death factor. Science (Wash DC). 267, 1449-1456 (1996).
4. Griffith, T. S. & Ferguson, T. A. The role of FasL-induced apoptosis in immune privilege. Immunol Today. 18, 240-244 (1997).
5. Houston, A. & O'Connell, J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol. 4, 321-326 (2004).
6. Sun, T. et al. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 96, 1030-1036 (2004).
7. Zhang, X. et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet. 42, 479-484 (2005).
8. Wu, J. et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene inAfrican American systemic lupus erythematosus patients. J Immunol. 170, 132-138 (2003).
9. Contreras, D. N. et al. Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes. J Immunother. 23, 67-74 (2000).
10. Kase, H., Aoki, Y. & Tanaka, K. Fas ligand expression in cervical adenocarcinoma relevance to lymph node metastasis and tumor progression. Gynecol Oncol. 90, 70-74 (2003).
11. Reesink-Peters, N. et al. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol. 96, 705-713 (2005).
12. Korkolopoulou, P. et al. c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. Histopathology. 51, 150-156 (2007).
13. Lee, W. C., Yu, M. C. & Chen, M. F. Prognostic impact of Fas ligand on hepatocellular carcinoma after hepatectomy. World J Surg. 28, 792-796 (2004).
14. Viard-Leveugle, I., Veyrenc, S., French, L. E., Brambilla, C. & Brambilla, E. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. J Pathol. 201, 268-277 (2003).
15. Nagashima, H. et al. Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis. Int J Onco. 18, 1157-1162 (2001).
16. Lerma, E. et al. Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma. Virchows Arch. 452, 65-74 (2008).
17. Okada, K. et al. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res. 6, 3560-3564 (2000).
18. Chen, L. et al. CD95 promotes tumour growth. Nature. 465, 492-496 (2010).
19. Bennett, M. W. et al. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut. 44, 156-162 (1999).
20. Huber, V. et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology. 128, 1796-1804 (2005).
21. Minas, V. et al. Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. Br J Cancer. 97, 637-645 (2007).
22. O'Connell, J., O'Sullivan, G. C., Collins, J. K. & Shanahan, F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 184, 1075-1082 (1996).
23. Sun, T. et al. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med. 202, 967-974 (2005).
24. Zhang, X. et al. Functional polymorphisms in cell death pathway genes Fas and FasL contribute to risk of lung cancer. J Med Genet. 42, 479-484 (2005).
25. Li, C. et al. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China. Pharmacogenet Genomics. 16, 245-251 (2006).
26. Wang, W. et al. Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett. 3, 625-628 (2012).
27. Li, C. et al. Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res. 14, 3230-3236 (2008).
28. Zhang, Z. et al. The FAS ligand promoter polymorphism, rs763110 (-844C. T), contributes to cancer susceptibility: evidence from 19 case-control studies. Eur J Hum Genet. 17, 1294-1303 (2009).
29. Ter-Minassian, M. et al. Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis. 29, 2147-2152 (2008).
30. Lei, D. et al. FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 19, 1484-1491 (2010).
31. Wu, M. et al. Smoking and alcohol drinking increased the risk of esophageal cancer among Chinese men but not women in a high-risk population. Cancer Causes Control. 22, 649-657 (2011).
32. Sun, T. et al. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 96, 1030-1036 (2004).
33. Sibley, K. et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 63, 4327-4330 (2003).
34. Bennett, M. W. et al. Fas ligand and Fas receptor are coexpressed in normal human esophageal epithelium: a potential mechanism of apoptotic epithelial turnover. Dis Esophagus. 12, 90-98 (1999).